RCUS earnings analysis
What we found in RCUS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Arcus Biosciences reported a significant drop in Q1 2026 revenue to $17 million, below the consensus estimate of $26.4 million. The company also experienced an EPS loss of $1.02, which actually beat estimates of -$0.85. Management predicts full-year revenue will be between $50 million and $65 million, indicating a lower outlook compared to previous expectations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline
- Total revenue dropped to $17 million from $28 million, a decrease of 39% year-over-year.
- Improved EPS vs Estimates
- Reported EPS loss of $1.02 beat estimates of -$0.85, showcasing better cost management.
- Cash Position Strong
- As of March 31, 2026, cash and equivalents stand at $876 million, sufficient to fund operations into 2028.
- R&D Expenses Stabilizing
- R&D expenses were flat at $122 million, with a shift in focus to late-stage development.
- Segment Revenue Breakdown
- License and development services revenue contributed $12 million, while other collaboration revenue was $5 million.
- Expectations for Future Revenue
- Management's guidance for full-year revenue is $50 million to $65 million, reflecting reduced optimism.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Declining Revenue Trend
- Total revenue decreased by 39% compared to Q1 2025, primarily due to lower development services revenue.
- High Operating Losses
- Net loss for Q1 2026 was $128 million compared to $112 million in the prior year, representing a 14% increase.
- Regulatory Uncertainties
- Risks associated with ongoing regulatory approvals and competitive pressures could delay product launches.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.02
- Segment
- License and Development Services: $12 million
- Segment
- Other Collaboration Revenue: $5 million
What they said about what is next.
Management expects full-year GAAP revenue to be between $50 million and $65 million.
The filing reads worse than the one before it.
What came before.
- 10-K · February 25, 2026
- Arcus presents a mixed 2025 picture: clinical progress on casdatifan (Phase 1/1b showed improved efficacy in ~120 late-line ccRCC patients and PEAK-1 is enrolling) and completed PRISM-1 enrollment in September 2025 with…
- 10-Q · May 6, 2025
- Arcus Biosciences reported a decline in revenue and an increased net loss for Q1 2025 compared to the previous quarter and previous year. The significant decrease in total revenue of 81% from $145 million in Q1 2024 to…
- 10-Q · November 6, 2024
- Arcus reported Q3 revenue of $48.0M (up from $32.0M YoY) driven by collaboration/license receipts, while loss from operations widened to $105M and net loss was $92M (EPS $(1.00)). The company holds a strong liquidity…
- 10-Q · May 8, 2024
- Arcus reported Q1 revenue of $145 million (vs $25 million in Q1 2023) and GAAP net loss of $4 million, or $(0.05) per share (vs $(80) million and $(1.09) in Q1 2023). Revenue was driven by collaboration/license activity…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RCUS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever